<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05030818</url>
  </required_header>
  <id_info>
    <org_study_id>POLICROSS</org_study_id>
    <nct_id>NCT05030818</nct_id>
  </id_info>
  <brief_title>Cross-over Study of Coronary Risk Factors With a Polypill</brief_title>
  <acronym>POLICROSS</acronym>
  <official_title>Cross-over Analysis of the Control of Coronary Risk Factors and Level of Platelet Inhibition With a Polypill</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundación para la Investigación Biosanitaria del Principado de Asturias</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fundación para la Investigación Biosanitaria del Principado de Asturias</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Open-label, randomized, cross-over study conducted in a single center, applied to patients&#xD;
      receiving a polypill with 100 mg of acetyl salicylic acid and different doses of ramipril and&#xD;
      atorvastatin for indication of secondary prevention according to clinical practice, with&#xD;
      objective of analyzing the level of systolic blood pressure and LDL-cholesterol in the same&#xD;
      patient in 2 different periods: one under treatment of 3 months with the polypill and another&#xD;
      of 3 months with the components separately.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The European Society of Cardiology indicates that reducing the frequency of administration is&#xD;
      the most effective measure to improve therapeutic adherence. Current guidelines recommend&#xD;
      with class I and level of evidence A the use of polypills.&#xD;
&#xD;
      A polypill, composed of 100 mg of acetylsalicylic acid and variable doses of atorvastatin and&#xD;
      ramipril, is approved for secondary prevention of cardiovascular disease and has also been&#xD;
      widely used in primary prevention.&#xD;
&#xD;
      Numerous studies have been carried out focusing on different designs of polypill in&#xD;
      cardiovascular prevention to study their efficacy, cost-effectiveness and administration&#xD;
      schedule. Specifically, that polypill already has an extensive literature. However, although&#xD;
      there are previous studies with a cross-over design with other types of polypill to assess&#xD;
      the effects on the control of arterial hypertension and LDL cholesterol, to date there has&#xD;
      never been a cross-over design study with the polypill compared to the administration of its&#xD;
      components separately in the control of blood pressure, lipid level and level of platelet&#xD;
      aggregation.&#xD;
&#xD;
      Patients will be randomized to polypill vs separate components. Each patient will receive a&#xD;
      follow-up visit per month for 6 months, of which will be 3 consecutive months with treatment&#xD;
      with the polypill in its corresponding dose and the remaining 3 months with the same drugs&#xD;
      separately.&#xD;
&#xD;
      Primary objectives: Systolic blood pressure level and LDL cholesterol. Secondary objectives:&#xD;
      Degree of platelet aggregation with thromboxane A2 kit, diastolic blood pressure level, total&#xD;
      cholesterol and HDL, level of patient satisfaction, degree of adherence to treatment, adverse&#xD;
      events.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 1, 2021</start_date>
  <completion_date type="Anticipated">August 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Each patient will be treated (Randomized) during 3 months with the polypill acetylsalicylic acid, ramipril and atorvastatin) and another 3 months with the same drugs and at the same doses than the polypill</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>LDL-cholesterol</measure>
    <time_frame>Months 2 and 3 vs. Months 5 and 6</time_frame>
    <description>Mean of absolute level of LDL cholesterol</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Systolic blood pressure</measure>
    <time_frame>Months 2 and 3 vs. Months 5 and 6</time_frame>
    <description>Mean of absolute level of systolic blood pressure</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">88</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>Polypill</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will be receiving the polypill at the adequate doses during 3 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Drugs taken separately</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will be receiving during 3 months the same components and at the same doses than with the polypill</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Polypill of acetylsalicylic acid, ramipril and atorvastatin</intervention_name>
    <description>Administration of acetylsalicylic acid, ramipril and atorvastatin in a polypill during 3 months more</description>
    <arm_group_label>Drugs taken separately</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Drugs taken separately: acetylsalicylic acid, ramipril and atorvastatin</intervention_name>
    <description>Patients will be receiving during 3 months more the same components acetylsalicylic acid, ramipril and atorvastatin than with the polypill</description>
    <arm_group_label>Polypill</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Patients over 18 years of age. Patients under treatment with the Trinomia® polypill in any&#xD;
        of its presentations for indication of secondary prevention and who can make the 6 visits&#xD;
        necessary to complete the study. Patients who sign the Informed Consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Patients who do not sign the informed consent. Patients with an inability to understand and&#xD;
        comply with the protocol. Patients with contraindication to any component of the polypill.&#xD;
        Patients who are already participating in another clinical trial. Patients with any&#xD;
        condition that limits life expectancy to &lt;1 year. Patients with programmed coronary&#xD;
        revascularization. Patients with coronary stent implantation in the last 12 months.&#xD;
        Patients treated with any antithrombotic drug in addition to acetylsalicylic acid, that is,&#xD;
        low molecular weight heparin, P2Y12 receptor inhibitors, or oral anticoagulants.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Iñigo Lozano, MD, PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital de Cabueñes, Gijon</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Iñigo Lozano Martinez-Luengas, MD, PHD</last_name>
    <phone>+34630901145</phone>
    <email>inigo.lozano@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital Universitario de Cabueñes</name>
      <address>
        <city>Gijón</city>
        <state>Asturias</state>
        <zip>33203</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <results_reference>
    <citation>Tamargo J, Castellano JM, Fuster V. The Fuster-CNIC-Ferrer Cardiovascular Polypill: a polypill for secondary cardiovascular prevention. Int J Cardiol. 2015 Dec;201 Suppl 1:S15-22. doi: 10.1016/S0167-5273(15)31028-7. Review.</citation>
    <PMID>26747390</PMID>
  </results_reference>
  <results_reference>
    <citation>Castellano JM, Sanz G, Peñalvo JL, Bansilal S, Fernández-Ortiz A, Alvarez L, Guzmán L, Linares JC, García F, D'Aniello F, Arnáiz JA, Varea S, Martínez F, Lorenzatti A, Imaz I, Sánchez-Gómez LM, Roncaglioni MC, Baviera M, Smith SC Jr, Taubert K, Pocock S, Brotons C, Farkouh ME, Fuster V. A polypill strategy to improve adherence: results from the FOCUS project. J Am Coll Cardiol. 2014 Nov 18-25;64(20):2071-82. doi: 10.1016/j.jacc.2014.08.021. Epub 2014 Sep 1.</citation>
    <PMID>25193393</PMID>
  </results_reference>
  <results_reference>
    <citation>Castellano JM, Verdejo J, Ocampo S, Rios MM, Gómez-Álvarez E, Borrayo G, Ruiz E, Ibáñez B, Fuster V; SORS investigators. Clinical Effectiveness of the Cardiovascular Polypill in a Real-Life Setting in Patients with Cardiovascular Risk: The SORS Study. Arch Med Res. 2019 Jan;50(1):31-40. doi: 10.1016/j.arcmed.2019.04.001. Epub 2019 Apr 19.</citation>
    <PMID>31101241</PMID>
  </results_reference>
  <results_reference>
    <citation>González-Juanatey JR, Tamargo J, Torres F, Weisser B, Oudovenko N. Pharmacodynamic study of the cardiovascular polypill. Is there any interaction among the monocomponents? Rev Esp Cardiol (Engl Ed). 2021 Jan;74(1):51-58. doi: 10.1016/j.rec.2019.11.008. Epub 2020 Jan 23. English, Spanish.</citation>
    <PMID>31983653</PMID>
  </results_reference>
  <results_reference>
    <citation>Marzal D, Rodríguez Padial L, Arnáiz JA, Castro A, Cosín J, Lekuona I, Guijarro C. Use of the cardiovascular polypill 40mg in secondary cardiovascular prevention. Clin Investig Arterioscler. 2018 Sep - Oct;30(5):240-247. doi: 10.1016/j.arteri.2018.04.004. Epub 2018 Jul 17. Review. English, Spanish.</citation>
    <PMID>30017176</PMID>
  </results_reference>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 30, 2021</study_first_submitted>
  <study_first_submitted_qc>August 30, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 1, 2021</study_first_posted>
  <last_update_submitted>August 30, 2021</last_update_submitted>
  <last_update_submitted_qc>August 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hypertension</keyword>
  <keyword>LDL-cholesterol</keyword>
  <keyword>Platelet inhibition</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Ramipril</mesh_term>
    <mesh_term>Atorvastatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

